Dermira, a Redwood City, Calif-based specialty biopharmaceutical company focused on developing medical dermatology products, today completed a $51m Series C financing.
Backers included existing investors Bay City Capital, New Enterprise Associates (NEA), Canaan Partners and UCB S.A. as well as new investors Apple Tree Partners, Aisling Capital, Rock Springs Capital, Sabby Capital and other healthcare investors.
Dermira is a specialty biopharmaceutical company focused on advancing differentiated medical dermatology products to dermatologists and their patients. It has a portfolio of five product candidates including three late-stage product candidates, Cimzia (certolizumab pegol), in development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe plaque psoriasis, DRM04, a topical treatment for hyperhidrosis, and DRM01, a topical sebum inhibitor for the treatment of acne.
In addition to the funding, the company also announced executive appointments with Andrew Guggenhime as Chief Operating Officer and Chief Financial Officer, Christine Conroy as Senior Vice President, Regulatory Affairs and Christine Ring as Vice President, Legal. In addition, it has expanded its board of directors with the appointments of Dr. David E. Cohen, Matthew Fust, Mark McDade and William Ringo.